Thyroid Disease and the Heart: The Most Underdiagnosed Cardiac Risk Factor in Women

Subclinical hypothyroidism affects 10 to 12 percent of women over 40, predominantly as Hashimoto’s thyroiditis. A 2020 NHANES analysis of 9,020 adults found that TSH above 5.6 mIU/L with normal free T4 was associated with all-cause mortality hazard ratio of 1.90, with cardiovascular disease mediating up to 13.7 percent of this association in women. Standard laboratory reference ranges call TSH up to 4.5 “normal,” missing the window where cardiac damage accumulates silently through impaired contractility, adverse lipid profiles, diastolic hypertension, and accelerated atherosclerosis.

She had been on levothyroxine for two years with a TSH of 4.8 and felt terrible. Her cardiologist checked free T3. It was very low. Her TSH was “normal.” Her tissue was not.

This scene plays out in my clinic weekly. A woman in her late forties with unexplained fatigue, rising cholesterol despite clean eating, blood pressure creeping upward, and a cardiologist who has checked everything except the obvious. Her primary care physician tested TSH eighteen months ago. It came back 4.2 mIU/L. The lab flagged it normal. The case closed.

Meanwhile, her LDL climbed 23 points. Her diastolic blood pressure sits at 92 mmHg. She gained twelve pounds without changing anything. Her resting heart rate increased from 68 to 82 beats per minute as her heart compensates for reduced stroke volume. She has been told she needs to exercise more and stress less.

She does not need lifestyle advice. She needs someone to check her free T3.

The Thyroid-Cardiac Axis: What Your Heart Actually Sees

The heart is a thyroid hormone target organ. Every cardiac myocyte expresses thyroid hormone receptors. T3, the active hormone, directly regulates the genes that control how your heart contracts and relaxes.

At the molecular level, T3 upregulates myosin heavy chain alpha (MHC-α) and sarcoplasmic reticulum calcium ATPase (SERCA2). These proteins determine the speed and force of cardiac contraction. T3 simultaneously suppresses phospholamban, a protein that inhibits calcium cycling. The net effect: efficient, rapid contraction and complete relaxation between beats. Klein & Ojamaa 2001

In hypothyroidism, this system fails. MHC-α expression drops. SERCA2 decreases. Phospholamban rises. The result is a heart that contracts slowly, incompletely, and relaxes poorly. Cardiac output drops 30 to 50 percent in severe hypothyroidism compared to the euthyroid state. 5 / Solid

But here is what most physicians miss: you do not need overt hypothyroidism for cardiac effects. Subclinical hypothyroidism, where TSH is elevated but free T4 remains technically normal, already impairs cardiac function. The Cardiovascular Health Study demonstrated that participants with TSH between 7.0 and 9.9 mIU/L had a 2.3-fold increased risk of incident heart failure compared to euthyroid controls, hazard ratio 2.33 with 95% confidence interval 1.10 to 4.96. Rodondi et al. 2008

Your heart does not wait for your TSH to hit 10.0 before it starts failing.

The Lipid Connection: Why Your Cholesterol Won’t Budge

I see it constantly. A woman in her late forties with LDL suddenly 30 points higher than her prior reading. She has not changed her diet. She exercises regularly. Her weight is stable. Her physician prescribes a statin.

Nobody checks her thyroid.

T3 directly regulates the hepatic LDL receptor. This receptor clears LDL particles from your bloodstream. When T3 drops, LDL receptor gene transcription decreases. Fewer receptors mean fewer LDL particles removed from circulation. The math is remarkably consistent: LDL rises 15 to 30 mg/dL for every 1 mIU/L increase in TSH above 4.0. Duntas & Brenta 2012 5 / Solid

A 2023 systematic review and meta-analysis of 80 studies confirmed that hypothyroidism is independently associated with elevated total cholesterol, elevated LDL, elevated triglycerides, and reduced HDL. Razvi et al. 2023 The relationship is dose-dependent. Even mild TSH elevation shifts lipids in the wrong direction.

This matters for treatment decisions. If you have a woman with rising LDL and TSH of 5.8, optimizing her thyroid function may drop her LDL more than a moderate-intensity statin. The 2023 ACC/AHA guidelines on chronic coronary disease now acknowledge thyroid dysfunction as a reversible cause of dyslipidemia that should be addressed before committing to lifelong lipid therapy.

Women don’t die from what they have. Women die from what they hold.

She holds TSH of 5.2 and LDL of 152. She holds the prescription for atorvastatin. She holds the belief that her thyroid is fine because the lab said normal. She holds the gradual accumulation of coronary plaque that no one traced back to its source.

Blood Pressure and the Hypothyroid Heart

Hypothyroidism causes hypertension through a mechanism that surprises most physicians. It is not the systolic pressure that rises first. It is the diastolic.

When cardiac output drops from thyroid deficiency, the body compensates by increasing systemic vascular resistance. The arterioles constrict to maintain perfusion pressure with reduced cardiac output. This constriction elevates diastolic pressure preferentially. The result: isolated diastolic hypertension or a narrowed pulse pressure.

The data are striking. Hypothyroid patients have 25 to 50 percent higher prevalence of diastolic hypertension (blood pressure above 140/90 mmHg) compared to euthyroid controls. A 2025 individual participant data analysis of 69,006 participants from 16 cohorts, mean age 59.6 years with 53% women, confirmed the association between subclinical thyroid dysfunction and cardiovascular risk factors. Gencer et al. 2025 5 / Solid

This creates a diagnostic trap. A 52-year-old woman presents with blood pressure of 138/94. Her physician starts lisinopril. Her TSH of 6.1 sits unchecked in last year’s chart, flagged normal by the lab’s outdated reference range. Her blood pressure barely budges despite dose increases because the underlying driver remains untreated.

I have watched blood pressures normalize within eight weeks of adequate thyroid replacement. Not every time. But often enough that I check TSH on every woman with new-onset hypertension, especially if the diastolic elevation predominates.

The TSH Controversy: What “Normal” Actually Means

Here is where medicine fails women most egregiously.

The standard laboratory reference range for TSH extends to 4.0 or 4.5 mIU/L in most American labs. This range was established decades ago using population samples that included individuals with undiagnosed thyroid disease. Epidemiologic data from iodine-sufficient populations without thyroid antibodies suggest the true upper limit of normal is closer to 2.5 mIU/L.

The NHANES analysis published in JAMA Network Open in 2020 made this concrete. Among 9,020 US adults followed for a median of 7.3 years, subclinical hypothyroidism defined as TSH above 5.6 mIU/L with normal free T4 was associated with all-cause mortality hazard ratio of 1.90, 95% confidence interval 1.14 to 3.19. Cardiovascular disease mediated 14.3 percent of this association overall. The mediation was most pronounced in women, ranging from 7.5 to 13.7 percent of the association. Ning et al. 2020 5 / Solid

Read that again. Women with TSH above 5.6, a level most labs call normal, had nearly double the mortality risk. Their cardiovascular disease explained a significant portion of that excess death.

The TRUST trial complicated matters. Published in 2017, it randomized adults over 65 with subclinical hypothyroidism (TSH 4.6 to 19.9 mIU/L) to levothyroxine versus placebo. No benefit emerged for blood pressure, symptom scores, or carotid intima-media thickness. Critics note the trial enrolled older adults, mean age 74, who may have already accumulated irreversible cardiovascular damage. The intervention may have come too late.

The clinical synthesis I use: in women under 65 with TSH above 7.0, symptoms consistent with hypothyroidism, and cardiovascular risk factors, treatment is reasonable. In women under 65 with TSH between 4.5 and 7.0, I check thyroid peroxidase antibodies. If positive, indicating Hashimoto’s, progression to overt hypothyroidism is likely, and early treatment may prevent the cardiac consequences we are trying to avoid.

Beyond TSH: The Free T3 Problem

The woman in my opening had a TSH of 4.8 on levothyroxine. By every standard metric, she was adequately treated. She was not.

TSH reflects pituitary feedback. It tells you what the pituitary thinks about circulating thyroid hormone. It does not tell you what the tissues see. The biologically active hormone is T3. Your body converts T4, the storage hormone, to T3 through deiodinase enzymes. This conversion happens primarily in peripheral tissues, not the thyroid.

Multiple factors impair T4-to-T3 conversion. Chronic inflammation suppresses deiodinase activity. Iron deficiency, rampant in premenopausal women, reduces conversion efficiency. Genetic polymorphisms in deiodinase genes affect conversion rates. Selenium deficiency impairs deiodinase function.

A woman can have adequate T4 on levothyroxine, a suppressed TSH confirming pituitary satisfaction, and tissue hypothyroidism from poor T3 conversion. Her free T3 sits in the lower third of the reference range. Her tissues starve while her labs look normal.

I check free T3 on every woman with persistent hypothyroid symptoms despite “adequate” levothyroxine dosing. If free T3 is below mid-range while TSH is in the lower half of normal, I address the conversion problem. This may mean treating underlying inflammation. It may mean correcting iron deficiency, which should be done anyway because iron deficiency itself causes cardiac symptoms. It may mean adding small doses of T3 to the T4 regimen.

This approach remains controversial in endocrinology circles. The American Thyroid Association guidelines do not endorse routine free T3 testing or combination T4/T3 therapy. However, a subset of women metabolize levothyroxine poorly, and their continued suffering under “best” therapy represents a failure of the algorithm-driven approach. 3 / Early

The Autoimmune Overlay: Hashimoto’s and Cardiac Inflammation

Hashimoto’s thyroiditis is not just low thyroid. It is an autoimmune disease. The immune system attacks thyroid tissue, causing inflammation that extends beyond the thyroid gland.

Women with Hashimoto’s have elevated high-sensitivity C-reactive protein independent of thyroid hormone levels. They have accelerated carotid intima-media thickness. They have higher rates of diastolic dysfunction on echocardiography even when TSH is controlled. Razvi et al. 2025 4 / Promising

This autoimmune inflammation follows the same pathways that drive coronary atherosclerosis. NF-kB pathway activation. Endothelial dysfunction. Oxidative stress. The thyroid antibodies are a marker of systemic immune dysregulation, not just thyroid-specific destruction.

For this reason, I treat Hashimoto’s as a cardiovascular risk factor independent of TSH level. A woman with TSH of 3.2, well within normal range, but thyroid peroxidase antibodies of 450 IU/mL has an inflammatory process that increases her cardiac risk. She needs anti-inflammatory lifestyle interventions. She needs cardiovascular risk factor monitoring. She may benefit from earlier statin therapy if her ASCVD risk is borderline.

The connection between autoimmune thyroid disease and cardiovascular disease parallels other autoimmune-cardiac links. Women with rheumatoid arthritis, lupus, and psoriasis all have elevated cardiovascular risk. Hashimoto’s belongs in this category, yet it rarely receives the same cardiovascular attention.

The Hyperthyroid Heart: When Too Much Is Dangerous

I have focused on hypothyroidism because it accounts for 90 percent of thyroid disease in women. But hyperthyroidism, whether from Graves’ disease, toxic nodules, or excessive thyroid hormone replacement, carries its own cardiac dangers.

Excess thyroid hormone causes atrial fibrillation. The risk is not subtle. Hyperthyroid patients have a 5-fold increased risk of developing atrial fibrillation compared to euthyroid individuals. Even subclinical hyperthyroidism, low TSH with normal free T4 and free T3, carries a 3-fold elevated AF risk.

The mechanism involves direct effects on atrial myocyte electrophysiology. T3 shortens the atrial refractory period and increases automaticity. The result is an atrium primed for chaotic electrical activity.

This matters for two populations. First, women with untreated hyperthyroidism who present with new-onset palpitations or atrial fibrillation. The treatment is not just rate control or anticoagulation. It is fixing the thyroid. Second, women on levothyroxine whose doses have crept upward over years, now running TSH below 0.3 mIU/L. They have iatrogenic subclinical hyperthyroidism, and their AF risk is elevated accordingly.

Hyperthyroidism also causes high-output heart failure. The heart rate increases. Contractility increases. Cardiac output rises. But demand outpaces supply. The heart fatigues from overwork. Women with prolonged untreated hyperthyroidism can develop irreversible dilated cardiomyopathy.

What to Ask For: The Specific Tests That Matter

Standard thyroid screening, TSH alone, is inadequate for cardiovascular risk assessment in symptomatic women. Here is the panel I order:

TSH. Still necessary. But interpret it against tighter thresholds. Above 4.0 mIU/L warrants further investigation in symptomatic women. Above 7.0 mIU/L warrants treatment discussion regardless of free T4 level.

Free T4. The storage hormone. Low free T4 with elevated TSH confirms primary hypothyroidism.

Free T3. The active hormone. Low free T3 with adequate free T4 identifies conversion problems. This test is the one most often omitted and most often illuminating.

Thyroid peroxidase antibodies (TPO-Ab). Positive in 90 percent of Hashimoto’s cases. Predicts progression from subclinical to overt hypothyroidism. Identifies the autoimmune inflammation that drives cardiovascular risk independent of TSH.

Thyroglobulin antibodies (TG-Ab). Positive in 60 percent of Hashimoto’s cases. Sometimes positive when TPO-Ab is negative.

Reverse T3. Controversial. Elevated in chronic illness, inflammation, and stress. May help explain persistent symptoms with normal TSH and free T3. Not endorsed by major guidelines but clinically useful in refractory cases. 3 / Early

At your next appointment, bring this list. Ask for these tests by name. If your physician resists, explain that you have cardiac symptoms, fatigue, or rising lipids that deserve complete thyroid evaluation. The cost of the full panel is trivial compared to the cost of undiagnosed thyroid-driven cardiovascular disease.

The Clinical Framework: The Thyroid Vascular Inflection Window

I think of thyroid disease through a concept I call the Thyroid Vascular Inflection Window. This is the period, typically spanning ages 40 to 55, when subclinical thyroid dysfunction begins manifesting as cardiovascular dysfunction.

During this window, subtle TSH elevations that went unnoticed at 35 become clinically significant. The same degree of hypothyroidism now intersects with declining estrogen, rising inflammatory markers, and accumulated vascular aging. The combination accelerates atherosclerosis in a way that neither factor would alone.

The window is also the best intervention period. Catch and correct thyroid dysfunction during this phase, and you may prevent irreversible cardiac remodeling. Wait until age 70, as the TRUST trial did, and the opportunity may have passed.

For women in this window, I recommend annual thyroid screening with the complete panel, not just TSH. If TSH trends upward over consecutive years, even within the “normal” range, that trend matters. A woman whose TSH went from 1.8 to 2.9 to 3.7 over three years has a trajectory. Waiting for it to hit 5.0 before acting is waiting for cardiovascular damage to accumulate.

Your Next Step

Do not accept a single TSH value as complete thyroid assessment. If you are a woman over 40 with any of the following: unexplained fatigue, rising LDL despite stable lifestyle, new-onset hypertension especially diastolic, palpitations, or weight gain without explanation, you need complete thyroid evaluation.

At your next appointment, request TSH, free T4, free T3, and TPO antibodies. If your TSH is above 4.0, request a repeat in six weeks to confirm. If your free T3 is in the lower third of the reference range while on levothyroxine, ask why. Print this article and bring it with you.

The connection between your thyroid and your heart is direct, documented, and treatable. The only barrier is recognition.

Frequently Asked Questions

Can thyroid problems cause heart palpitations in women?

Yes. Both hyperthyroidism and hypothyroidism cause palpitations, but through different mechanisms. Hyperthyroidism shortens the atrial refractory period and increases atrial automaticity, raising atrial fibrillation risk 5-fold compared to euthyroid individuals. Even subclinical hyperthyroidism with low TSH but normal free T4 triples AF risk. Hypothyroidism causes compensatory tachycardia as the heart attempts to maintain cardiac output despite reduced stroke volume per beat. If you have new palpitations, do not accept TSH alone. Ask for free T3, free T4, and TSH together. The pattern of results will distinguish between too little and too much thyroid hormone and guide appropriate treatment.

What TSH level increases heart disease risk?

The evidence is clearer than standard reference ranges suggest. In the NHANES cohort of 9,020 adults, TSH above 5.6 mIU/L with normal free T4 was associated with all-cause mortality hazard ratio of 1.90, meaning nearly double the death risk over 7.3 years of follow-up. The Cardiovascular Health Study showed TSH between 7.0 and 9.9 mIU/L increased heart failure risk 2.3-fold. Most American labs call TSH up to 4.5 mIU/L “normal.” This cutoff misses significant cardiovascular risk, particularly in women. If your TSH is above 4.0 and you have symptoms or cardiovascular risk factors, you deserve further evaluation regardless of what the lab flags as normal.

Should I take levothyroxine if I have subclinical hypothyroidism?

The answer depends on your age, TSH level, symptom burden, and antibody status. If you are under 65 with TSH above 7.0 mIU/L, symptoms consistent with hypothyroidism such as fatigue, cold intolerance, or weight gain, and cardiovascular risk factors like elevated LDL, treatment often provides benefit. The evidence for treatment in TSH between 4.5 and 7.0 is less strong, but if you have positive thyroid peroxidase antibodies indicating Hashimoto’s, progression to overt hypothyroidism is likely. Early treatment may prevent the cardiovascular consequences that develop during the years of subclinical disease. In adults over 65, the TRUST trial showed no clear benefit, and the risk-benefit calculation shifts.

Why do I still feel terrible on thyroid medication with normal TSH?

This question reflects a genuine clinical phenomenon that standard endocrinology practice handles poorly. TSH reflects pituitary feedback to circulating thyroid hormone. It does not directly measure what your tissues see. The biologically active hormone is T3, which your body produces by converting T4 through deiodinase enzymes. Inflammation, iron deficiency, selenium deficiency, and genetic variants can impair this conversion. You can have adequate T4 on levothyroxine, a suppressed TSH confirming the pituitary is satisfied, and tissue hypothyroidism from poor T3 production. Check your free T3. If it sits in the lower third of the reference range while your TSH is well-controlled, you likely have a conversion problem that warrants further investigation and potentially treatment adjustment.

Does Hashimoto’s thyroiditis increase heart disease risk beyond low thyroid hormone?

Yes. Hashimoto’s is an autoimmune disease, not just a cause of hypothyroidism. The chronic immune activation drives systemic inflammation through the same pathways that promote atherosclerosis: NF-kB activation, endothelial dysfunction, and oxidative stress. Women with Hashimoto’s have elevated high-sensitivity C-reactive protein, accelerated carotid intima-media thickness, and higher rates of diastolic dysfunction on echocardiography even when TSH is controlled with replacement therapy. The thyroid peroxidase antibodies that diagnose Hashimoto’s mark systemic immune dysregulation, not just thyroid-specific damage. This is why I treat Hashimoto’s as an independent cardiovascular risk factor and counsel anti-inflammatory lifestyle interventions even when TSH is optimized.